Introduction Gonadotropin-releasing hormone analogs (GnRHa) are the treatment of choice
for CPP. We investigated growth in GnRHa-naïve subjects, treated with leuprolide acetate 1 …

Context: GnRH agonist (GnRHa) monthly injections are frequently used in the treatment of
central precocious puberty (CPP). The 3-month leuprolide depot 11.25-and 30-mg …

Context Gonadotropin-releasing hormone agonists (GnRHas) are standard of care for
central precocious puberty (CPP). A 6-month subcutaneous injection has recently been …

Background: Children with central precocious puberty (CPP) are treated with gonadotropin-
releasing hormone agonists (GnRHa) to suppress puberty. Optimizing treatment outcomes …

Context: We have recently demonstrated short-term (6-month) efficacy and safety of
leuprolide acetate 3-month depot 11.25 and 30 mg in children with central precocious …

Objective Gonadotropin-releasing hormone agonists (GnRHa) are the treatment of choice
for central precocious puberty (CPP) and have been widely used for several decades. We …

Objectives Gonadotropin-releasing hormone agonist treatment is important for optimal
growth in girls with central precocious puberty (CPP). Data are lacking regarding benefit to …

Methods. This prospective US multicenter trial of leuprolide acetate 1-month depot (7.5–15
mg) for central precocious puberty utilized an open-label treatment period, long-term follow …

Objective: Doses of gonadotropin releasing hormone (GnRH) analogues used to treat
idiopathic central precocious puberty (iCPP) vary among clinicians. Study aims were to …

Objective Gonadotropin-releasing hormone agonist (GnRHa) treatment improves the
potential for gaining height in patients with central precocious puberty (CPP). However, most …